Romark IVA - Digital PDF interaction 10.13

Patient Journey: CDC Study
4
In a recent publication of U.S. insurance claims of 3,000 patients with giardiasis evaluating
diagnosis and treatment practices, it was observed that patient care can be improved 3
Missteps in diagnosis or treatment
Only 18% of patients had a Giardia-specific test followed
by an antiparasitic medication effective against giardiasis 3
27% of patients received a systemic antibiotic ineffective
against Giardia 3
Of 1,000 surveyed pediatricians, approximately 10% said
they would suspect parasites in patients with persistent
diarrhea lasting more than 1 – 2 weeks 4
50% of patients had 3 or more visits to the clinic during
the study window 3
Chronic or persistent disease
22% of patients (n = 657) waited >30 days from their first GI
symptom visit to their first visit with a giardiasis diagnosis 3
Nearly 40% of patients (n=1,192) endured symptoms or
waited for a diagnosis for more than 1-month 3
Following acute infection, giardiasis might also lead to
long-term chronic disease, including IBS 3,5 †
Awareness of parasitic infections can enhance
selection of appropriate treatments and potentially
alleviate the patient’s symptoms earlier
†
Nitazoxanide is not indicated for diarrhea caused by IBS
*Indications
ALINIA ® for Oral Suspension (patients 1 year of age and older) and ALINIA Tablets (patients 12 years and older)
are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Limitations of Use: ALINIA for Oral Suspension and ALINIA Tablets have not been shown to be effective for the
treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients.
Important Safety Information
• ALINIA Tablets and ALINIA for Oral Suspension are contraindicated in patients with a prior hypersensitivity
to nitazoxanide or any other ingredient in the formulations.